Lupin has informed that it has enclosed is a Press Release on 9th March 2021 titled ‘Lupin Pharma Canada Announces Partnership with Endoceutics for the commercialization of Intrarosa®’as regards Lupin Pharma Canada, Canada/wholly owned subsidiary of the Company having entered into partnership with Endoceutics, a women's health focused innovative Canadian biotech company, to commercialize Intrarosa® in Canada indicated for the treatment of postmenopausal vulvovaginal atrophy offered as a vaginal ovule containing 6.5 mg of Prasterone. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
